Narrow your search

Library

FARO (1)

KU Leuven (1)

LUCA School of Arts (1)

Odisee (1)

Thomas More Kempen (1)

Thomas More Mechelen (1)

UCLL (1)

ULB (1)

ULiège (1)

VIVES (1)

More...

Resource type

book (3)


Language

English (3)


Year
From To Submit

2020 (3)

Listing 1 - 3 of 3
Sort by

Book
Outcomes and Therapeutic Management of Bladder Cancer
Author:
Year: 2020 Publisher: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.

Keywords

Medicine --- bladder cancer --- robotic-assisted --- open --- radical cystectomy --- survival --- propensity score --- age --- urothelial carcinoma --- outcome --- anesthesia recovery periods --- cognitive impairment --- gamma-cyclodextrins --- neuromuscular blockade --- robotic radical cystectomy --- glycogen --- clear-cell adenocarcinoma --- urinary bladder --- SEER program database --- female --- intracorporeal neobladder --- outcomes --- robotic --- sex-sparing --- methylation --- biomarkers --- FOXA1 --- GATA3 --- KRT20 --- molecular markers --- mRNA --- muscle-invasive bladder cancer --- PCR --- human epidermal growth factor receptor 2 --- indoleamine 2,3-dioxygenase --- programmed death ligand-1 --- immunotherapy --- nodal disease --- pN1 --- neoadjuvant --- adjuvant --- chemotherapy --- bladder cancer --- robotic-assisted --- open --- radical cystectomy --- survival --- propensity score --- age --- urothelial carcinoma --- outcome --- anesthesia recovery periods --- cognitive impairment --- gamma-cyclodextrins --- neuromuscular blockade --- robotic radical cystectomy --- glycogen --- clear-cell adenocarcinoma --- urinary bladder --- SEER program database --- female --- intracorporeal neobladder --- outcomes --- robotic --- sex-sparing --- methylation --- biomarkers --- FOXA1 --- GATA3 --- KRT20 --- molecular markers --- mRNA --- muscle-invasive bladder cancer --- PCR --- human epidermal growth factor receptor 2 --- indoleamine 2,3-dioxygenase --- programmed death ligand-1 --- immunotherapy --- nodal disease --- pN1 --- neoadjuvant --- adjuvant --- chemotherapy


Book
Outcomes and Therapeutic Management of Bladder Cancer
Author:
Year: 2020 Publisher: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.


Book
Outcomes and Therapeutic Management of Bladder Cancer
Author:
Year: 2020 Publisher: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.

Listing 1 - 3 of 3
Sort by